Journal
EXPERIMENTAL BIOLOGY AND MEDICINE
Volume 233, Issue 5, Pages 522-534Publisher
SAGE PUBLICATIONS LTD
DOI: 10.3181/0708-MR-226
Keywords
cancer vaccines; immunotherapy; combination therapy; prostate cancer
Categories
Funding
- Intramural NIH HHS [Z01 BC010945-01, Z01 BC010662-04, Z01 BC010666-04] Funding Source: Medline
Ask authors/readers for more resources
Cancer vaccines constitute a unique therapeutic modality in that they initiate a dynamic process involving the host's immune response. Consequently, (a) repeated doses (vaccinations) over months may be required before patient clinical benefit is observed and (b) there most likely will be a dynamic balance between the induction and maintenance of host immune response elements to the vaccinations vs. host/tumor factors that have the potential to diminish those responses. Thus patient response in the form of disease stabilization and prolonged survival may be more appropriate to monitor than strictly adhering to tumor response in the form of Response Criteria In Solid Tumors (RECIST) criteria. This can be manifested in the form of enhanced patient benefit to subsequent therapies following vaccine therapy. This article will review these phenomena unique to cancer vaccines with emphasis on prostate cancer vaccines as a prototype for vaccine therapy. The unique features of this modality require the consideration of paradigm shifts both in the way cancer vaccine clinical trials are designed and in the way patient benefit is evaluated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available